logo
Confused and disoriented pets? Dementia is not just for humans

Confused and disoriented pets? Dementia is not just for humans

Yahoo19-05-2025
Sometimes the little guy just stops and doesn't know where he is any more. At 15 years old, Olli the pug is very old, in need of help, often disoriented. He doesn't hear or see much and his hind legs hurt.
"Olli has had dementia for a few years," says owner Ute Hausmann. She has completely adjusted to his needs, caring for, nurturing, looking after and encouraging the animal that has been living with her and her husband in the Rheinisch-Bergisch district near Cologne for 11 years. Because: "Olli is dearly loved."
Dementia widespread among older dogs and cats
According to Holger Volk, a doctor at the University of Veterinary Medicine Hanover, dementia is common among dogs and cats of an advanced age.
He says that about one in three dogs aged 12 to 13 years show clinical symptoms.
By the age of 15 to 16, two out of three dogs are affected by "canine cognitive dysfunction syndrome."
And among very old cats at about 16 years of age, around 50% have dementia, known as "feline" syndrome. So, all in all, a "huge number," he says.
Early intervention is very important. "When pet owners notice abnormalities, it is often almost too late," says Volk, who heads the hospital for small animals.
The disease is difficult to diagnose because the signs vary and dementia develops progressively. It is usually accompanied by other illnesses and not easily separated from "normal" degenerative signs of old age.
What causes dementia and what to watch for?
Changes in an animal's brain metabolism, inflammation and protein deposits all cause nerve cells to no longer work properly. Those changes make an animal slow down and some forget practised commands. They may get confused and no longer sleep well – and there are also behavioural changes.
"Loner behaviour and withdrawal" are examples Volk cites. Joint pain and dental disease are common.
Prevention can help. Measures can include a suitable low-sugar diet – with certain fatty acids that work as energy sources for older animals and prevent inflammatory reactions.
If dementia is diagnosed, special food is definitely part of a treatment strategy. Exercise and mental stimulation are also key.
"There are not many medications available" – except for a stimulant to help with persistent poor sleep or a means to promote blood circulation, says Volk.
So it is important to observe your animal carefully for any changes.
Cats: Harder to watch closely
Cats like to do their own thing – and therefore tend to slip under the radar and out of sight. But signs of dementia in cats can include appearing anxious, becoming less active and interacting less, the veterinarian says.
It is also very common for cats to meow loudly, almost scream at night, a sign the animal is trying to locate itself.
A cat may also struggle to find its litter tray – just as a normally house-trained dog may stop indicating when it has to go and instead relieve itself in the home, according to the animal welfare foundation Four Paws.
Dementia brings changes not only for the affected animals, but also for their families. But with patience and the right care, the progression of the incurable disease can be slowed down.
As for the senior pug Olli, exercise and a routine are very important. Owner Hausmann massages her pug's aching hind legs every morning. Then she takes him out two to three times a day – always the same familiar short distances and very slowly.
"It helps him to cope," she says.
Even a curb can pose a challenge. After the short walk, the 74-year-old lifts the 9-kilogram bundle onto the sofa at home. "Olli used to be very boisterous and lively. Now he's slow, unsure of himself and always wants to be where I am, constantly following me around."
Engaging with other four-legged friends is out of the question.
"He doesn't want anything to do with other dogs any more. He used to be in a good mood, was very interested in females, but now he doesn't like any contact at all."
At night, her pug often wakes up and seems completely lost. "Olli has a cautious, gentle character, he's not aggressive and luckily he still goes to the toilet outside," says Hausmann.
He manages to make himself noticed – and then he's out the front door and into the garden.
Hausmann, a former nursery school teacher who knows her pug inside out, doesn't miss a beat. Converted into human years, Olli is almost 100 years old.
Growing awareness of older animals' needs
Veterinarian Volk has observed that many pets are now living to a ripe old age, and this has led to a growing awareness of the issue.
However, he says doctors often only diagnose and treat concomitant diseases such as heart, kidney or joint problems. "The brain is not the focus of attention, but it is becoming more and more so."
He knows that it often helps pet owners when they receive clarity and a confirmed diagnosis of dementia.
Similar to humans, the same applies to dogs and cats: Age is a risk factor, but not a cause of dementia, he says. "We need to work much harder on prevention. A happy life includes a healthy brain."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jeff Bezos' mom's death spotlights Lewy body dementia symptoms and risks
Jeff Bezos' mom's death spotlights Lewy body dementia symptoms and risks

Fox News

time10 hours ago

  • Fox News

Jeff Bezos' mom's death spotlights Lewy body dementia symptoms and risks

Jacklyn "Jackie" Gise Bezos, the mother of Jeff Bezos, died last week at 78 after battling Lewy body dementia (LBD). The Amazon founder announced Jacklyn Bezos' death on Instagram, remembering her as a young mother who "pounced on the job of loving me with ferocity." "She always gave so much more than she ever asked for," he wrote in the caption. Jackie Bezos was diagnosed with LBD in 2020, according to her son, who noted that she "battled with the same dignity and courage that's shaped every aspect of her life." Jeff Bezos detailed that after a "long fight" with the neurological disorder, his mother passed away surrounded by "so many of us who loved her." "We were all so lucky to be in her life," he said. "I hold her safe in my heart forever." The National Institute on Aging (NIA) describes LBD as a "complex and challenging" progressive brain disorder. Abnormal protein deposits called Lewy bodies affect chemicals in the brain, which can lead to problems with thinking, movement, behavior, mood and other functions. Early LBD symptoms can include changes in mood, vision and body functions like heart rate and digestion, the NIA and Mayo Clinic have reported. It can also cause sleep issues, such as disorders like insomnia and restless leg syndrome. Cognitive symptoms of LBD can include changes in thinking abilities, drowsiness, attention issues and visual hallucinations, the above sources stated. LBD patients may also experience changes in mood and behavior like depression, anxiety, agitation, delusions or paranoia. These symptoms can often be confused with Alzheimer's disease. Physical symptoms can include slowness, muscle rigidity or stiffness, shuffling while walking, tremors or shaking, balance problems, stooped posture, loss of coordination, smaller handwriting, reduced facial expression, difficulty swallowing and a weak voice, Cleveland Clinic listed. Other miscellaneous symptoms may occur, such as blood pressure complications, difficulty regulating body temperature, fainting, frequent falls, constipation, urinary incontinence and poor sense of smell. LBD mostly affects people over the age of 50 and slightly impacts men more than women. Those with a family history of LBD or Parkinson's disease are at a greater risk, according to Mayo Clinic. The condition can occur alone or along with other brain disorders, as people with Lewy bodies in the brain can also have the "plaques and tangles" associated with Alzheimer's, the above source reports. As LBD is a progressive disease, symptoms will begin slowly and worsen over time, spanning an average of five to seven years from diagnosis to death — although the disease span can range from two to 20 years. People experiencing symptoms may visit a primary care doctor, who will most likely refer them to a neurologist for proper diagnosis, the NIA noted. Geriatric psychiatrists, neuropsychologists and geriatricians may also be able to diagnose the condition through testing and brain imaging. Although there is currently no cure for LBD, research is improving, according to the NIA, and some symptoms may respond to treatments. "Advances in science may one day lead to better diagnosis, improved care and new treatments," the NIA website states.

Help! My Patient Asked Me About Their Smartwatch HRV Status!
Help! My Patient Asked Me About Their Smartwatch HRV Status!

Medscape

time10 hours ago

  • Medscape

Help! My Patient Asked Me About Their Smartwatch HRV Status!

In recent years, smartwatches have gained popularity across Europe, driven by an increase in health awareness, smartphone integration, and advancements in wearable technology. They are now able to monitor an increasing number of health metrics, including the now-popular heart rate variability (HRV). So what happens when a patient comes to the clinic worried about their HRV status, as reported by their watch? To learn more about HRV and its clinical significance, Medscape Medical News spoke with two experts. Professor Thomas Gronwald, PhD, is head of the Department of Performance, Neuroscience, Therapy and Health at MSH Medical School Hamburg, Germany. He is an exercise and training scientist with a focus on internal and external load analysis in strength and conditioning training. Cailbhe Doherty, PhD, is an assistant professor at the School of Public Health, Physiotherapy, and Sports Science at University College Dublin, Ireland. His research is dedicated to investigating the effectiveness of consumer wearables in public health and the integration of mobile technologies in healthcare systems. What is HRV? And is it possible for smartwatches/wearables to accurately measure it? Thomas Gronwald, PhD Doherty: HRV is the variation in time between successive heartbeats. So even if your heart is beating at 60 beats/min, that doesn't mean it's beating exactly once every second. There are tiny fluctuations between beats — sometimes 0.98 seconds, sometimes 1.02 — and that variation is what we call HRV. Those fluctuations aren't random. They're governed by your autonomic nervous system…and within that system, there's a kind of balance: the sympathetic branch, which speeds things up (fight or flight), and the parasympathetic branch, which slows things down (rest and digest). HRV reflects that balance. In simple terms, a higher HRV generally indicates a more adaptable, resilient nervous system, and it's often used as a proxy for recovery, stress, and overall cardiovascular health. Gronwald: The gold standard for a valid and reliable assessment of the time between two successive heartbeats is the electrocardiogram (ECG), which allows recordings in the laboratory or during daily activity — up to 24 hours or longer. Several mobile and user-friendly measurement systems and wearables exist, which can record R-R intervals with different applications and form factors — chest strap systems, adhesive patches, and electrode systems on the skin — that utilize not only electrophysiologic but also optically derived signals such as photoplethysmography…. Most commercially available portable devices show a low absolute error under resting conditions but should always be validated against reference measures to clarify the accuracy of data parameters and maximize real-world application value. Is HRV an important measure of someone's health? Is it an important measure for an athlete? Doherty: Yes, but with some important qualifications. HRV can be a valuable indicator of health, but it's not a silver bullet. In a general health context, higher HRV is often associated with better cardiovascular health, lower levels of chronic stress, and even reduced risk for mortality…. It's a useful window into your overall resilience. The issue is that HRV is highly individual. What's high for one person might be low for another. It's not the kind of measure where a single value tells the whole story. You really need to look at trends over time and ideally interpret them in the context of things like sleep, recovery, illness, and training load. Gronwald: The usefulness of HRV as an indicator of physiologic and pathologic conditions, for risk stratification, and as a marker of autonomic adaptive and regulatory capacity is evident. However, longitudinal data recordings are recommended when trend analysis with contextual data is intended. Considering the mentioned context-sensitive requirements, HRV analysis allows for longitudinal trend analysis of patients and healthy individuals, including athletic and nonathletic populations in various clinical and performance-related settings. This includes the application of HRV monitoring for resting conditions, during and/or after biofeedback and training interventions, as well as general relationships between recovery status, previous exercise conditions, and symptoms of overreaching and overtraining. What should a doctor do if someone goes to them saying their smartwatch is showing that they continuously have a low HRV status? Cailbhe Doherty, PhD Doherty: I'd suggest it should be treated as a starting point. The physician might ask: Has this person noticed other symptoms — fatigue, poor sleep, high stress? Has their resting heart rate changed? Are there lifestyle factors — alcohol, illness, overtraining, or mental health — that could explain the trend? And if it seems warranted, they could conduct more standardized assessments, such as an ECG-based HRV measurement or a broader autonomic function test. The data is not medical grade and we don't know enough about how the proprietary algorithms are processing the signals. But if the question is whether the HRV trend might reflect something real, then yes, it's possible. Ultimately, I think wearables are better at raising questions than answering them. And that's not a bad thing. Is such data reliable? Gronwald: This depends strongly on the wearable or recording device. The measurement principles and the type of analysis and processing of the biosignal vary significantly between different devices. On the one hand, sleep analyses are used during the night, while on the other hand, context-free time points during the day are often used. Here, care should be taken to include standardized situations for a measurement and interpretation context. It is recommended to use validated measurement systems that either use the entire night as a reference phase or a consistent measurement situation early in the morning after waking up without prior stressors. Both approaches have advantages and disadvantages. How can someone improve their HRV? Gronwald: HRV improves when the body is balanced between activity and recovery within hemodynamic boundaries, with strong support from sleep, stress reduction, and a healthy active lifestyle. Regular physical activity, especially moderate aerobic exercise — such as walking, cycling, or swimming — and strength training can increase HRV over time. Breathing exercises with slow, deep, and diaphragmatic breathing — for example 4-6 breaths per minute — can help to activate the parasympathetic nervous system, which improves HRV. Good sleep quality with consistent sleep patterns, enough deep sleep, and avoiding late-night screen time and activity are essential for higher HRV. Further, stress management and practices such as meditation, social connection, mindfulness, or progressive muscle relaxation are linked to emotional well-being and can reduce stress and therefore improve HRV. Finally, healthy nutrition habits such as a balanced diet rich in whole foods, omega-3 fatty acids, fruits, and vegetables supports HRV — including limitation of stimulants, alcohol, nicotine, and processed foods. How important do you think wearable technology is to support the provision of healthcare across Europe? What role do you think it will play in the future? Doherty: Healthcare systems across Europe are facing enormous pressure: aging populations, rising chronic disease, long waiting lists, and constrained resources. Wearables offer something really compelling in that context: the ability to monitor people continuously, passively, and remotely, outside the clinic, in real-world settings. [But] at the moment, most wearable data isn't integrated into the healthcare system. It lives in consumer ecosystems — Apple, Google, Fitbit, Garmin — and that creates problems around standardization, privacy, and clinical utility. We can't expect a GP or a cardiologist to wade through raw data from 10 different apps and figure out what it means. There are also big equity issues. Most wearables are still designed and validated in relatively narrow populations — usually younger, healthier, often White, middle-income users. If we start using wearable data in clinical decision-making, we need to be absolutely sure it's valid across diverse populations, otherwise we risk baking health inequalities into digital health systems. Another issue is data privacy. When we start linking consumer data to clinical records, the stakes get much higher. Who owns the data? Who profits from it? Who gets access to it? Ultimately, I think wearables will play an increasingly important role in population health monitoring, early detection, and personalized prevention. But for that to happen in a way that is safe, effective, and fair, we need interoperability, regulatory oversight — especially on algorithm transparency, robust validation in real-world populations, and a clear framework around data rights and governance. Gronwald and Doherty reported no relevant financial relationships.

Madrigal wins European MASH approval as Novo rivalry looms
Madrigal wins European MASH approval as Novo rivalry looms

Yahoo

time15 hours ago

  • Yahoo

Madrigal wins European MASH approval as Novo rivalry looms

Madrigal Pharmaceuticals' Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, making it the first targeted therapy available for patients in the region with this severe form of liver disease. The conditional marketing authorisation by the European Commission (EC) follows an approval recommendation by the European Medicines Agency (EMA)'s Medicinal Products for Human Use (CHMP) in June. US pharma Madrigal expects to launch Rezdiffra in Europe on a country-by-country basis, starting with Germany in Q4 2025, as per a 19 August statement. Stock in US-listed Madrigal closed 2.2% down to $379.55 per share at market close on 19 August, with investors likely downbeat amid a tangential development. Viking's oral glucagon-like peptide-1 receptor agonist (GLP-1RA) drug posted disappointing trial results on the same day; Madrigal recently outlaid $2bn in an oral GLP-1RA licensing deal. The regulatory approval means Madrigal is the only pharmaceutical company with an approved MASH drug in Europe. Rezdiffra was also the first MASH treatment to market in the US – winning US Food and Drug Administration (FDA) approval in March 2024. MASH develops when there is a significant buildup of fat in the liver. Fibrosis, also known as scarring, is associated with MASH, and left untreated, it can lead to more serious damage, including cirrhosis. Madrigal estimates that approximately 370,000 patients have been diagnosed with MASH with moderate to advanced fibrosis in Europe. The disease is a form of non-alcoholic fatty liver disease (NAFLD) that has been billed as one of pharma's highest potential growth areas. Analysis by GlobalData forecasts sales of $25.7bn in 2032 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan), meaning Madrigal's first-to-market credentials in both the US and Europe could bode well for the drug's growth. GlobalData forecasts a high ceiling for Rezdiffra. The drug is expected to reach blockbuster status by the end of 2026, and, by 2031, Rezdiffra is forecast to generate $4.8bn in global sales. GlobalData is the parent company of Pharmaceutical Technology. Administered as a daily pill, Rezdiffra works by activating a thyroid hormone receptor that reduces liver fat accumulation. While Madrigal was first to reach market in the US for a MASH treatment, it has since lost its crown of boasting the only approved therapy in the indication. Earlier this week, Novo Nordisk's blockbuster drug Wegovy (semaglutide) won FDA approval for the treatment of MASH with moderate to advanced liver fibrosis, providing direct competition to Rezdiffra. Novo Nordisk has also applied for regulatory approval in the EU, setting up a second potential rivalry with Madrigal. However, unlike Wegovy, which exerts its effect through agonism of the GLP-1 receptors, Madrigal's treatment works directly in the liver itself. GlobalData senior analyst Jay Patel says: "This approval allows Madrigal's Rezdiffra to establish an early lead in the EU MASH market. Nevertheless, Novo Nordisk's Wegovy is set to follow closely behind, with an approval expected imminently. "It remains to be seen whether Rezdiffra will be able to carve out a niche once this takes place, given greater patient and physician familiarity with Wegovy, which is already approved for common MASH comorbidities such as obesity and type 2 diabetes mellitus." The EC based its approval on results from the Phase III MAESTRO-NASH trial, in which Rezdiffra achieved both fibrosis reduction and MASH resolution primary endpoints. The pill also reduced liver stiffness, liver fat, liver enzymes, and atherogenic lipids in the MAESTRO-NASH trial, and improved health-related quality of life. Madrigal's CEO Bill Sibold said: 'MASH is the fastest-growing indication for liver transplantation in Europe, but until now, it had no approved treatment. The European labelling for Rezdiffra will set an important precedent for the entire field, with no biopsy required to qualify for treatment with Rezdiffra and a clear focus on a distinct MASH patient population with high unmet need.' Before Madrigal and Novo's approvals, MASH had become a graveyard of failed candidates. Gilead, AstraZeneca, and Intercept all fell short in getting candidates to market, all eventually pivoting pipelines away from the indication. "Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store